Event-free survival
Fig. 5 · Panel A
Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, Karen Pinilla Alba, Alimu Dayimu, Nikolaos Demiris, Caron Harvey, Lynsey M Drewett, Rebecca Lucey, Alexander Fulton, Anne N Roberts, Joanna R Worley, Ms Anita Chhabra, Wendi Qian, Jessica Brown, Richard Hardy, Anne-Laure Vallier, Steve Chan, Maria Esther Una Cidon, Elizabeth Sherwin, Amitabha Chakrabarti, Claire Sadler, Jen Barnes, Mojca Persic, Sarah Smith, Sanjay Raj, Annabel Borley, Jeremy P Braybrooke, Emma Staples, Lucy C Scott, Cheryl A Palmer, Margaret Moody, Mark J Churn, Domenic Pilger, Guido Zagnoli-Vieira, Paul W G Wijnhoven, Mukesh B Mukesh, Rebecca R Roylance, Philip C Schouten, Nicola C Levitt, Karen McAdam, Anne C Armstrong, Ellen R Copson, Emma McMurtry, Susan Galbraith, Marc Tischkowitz, Elena Provenzano, Mark J O'Connor, Helena M Earl, PARTNER Trial Group
Nat Commun 16(1) 4269
Poly (ADP-ribose) polymerase inhibitors (PARPi) exploit DNA repair deficiency in germline BRCA1 and BRCA2 pathogenic variant (gBRCAm) cancers. Haematological toxicity limits chemotherapy-PARPi treatment combinations. In preclinical models we identified a schedule combining olaparib and carboplatin that avoids enhanced toxicity but maintains anti-tumour activity. We investigated this schedule in a neoadjuvant, phase II-III, randomised controlled trial for gBRCAm breast cancers (ClinicalTrials.gov ID:NCT03150576; PARTNER). The research arm included carboplatin (Area Under the Curve 5, 3-weekly); paclitaxel (80 mg/m2, weekly) day 1, plus olaparib (150 mg twice daily) day 3-14 (4 cycles), followed by anthracycline-containing chemotherapy (3 cycles); control arm gave chemotherapy alone. The primary endpoint, pathological complete response rate, showed no statistical difference between research 64.1% (25/39); control 69.8% (30/43) (p = 0.59). However, estimated survival outcomes at 36-months demonstrated improved event-free survival: research 96.4%, control 80.1% (p = 0.04); overall survival: research 100%, control 88.2% (p = 0.04) and breast cancer specific survival: research 100%, control 88.2% (p = 0.04). There were no statistical differences in relapse-free survival and distant disease-free survival, both were: research 96.4%, control 87.9% (p = 0.20). Similarly, local recurrence-free survival and time to second cancer were both: research 96.4%, control 87.8% (p = 0.20). The PARTNER trial identified a safe, tolerable schedule combining neoadjuvant chemotherapy with olaparib. This combination demonstrated schedule-dependent overall survival benefit in early-stage gBRCAm breast cancer. This result needs confirmation in larger trials.
1 个 Figure · 6 个 KM 面板
Kaplan–Meier curves of time to event outcomes. A Event-free survival by treatment arm (control vs research). B Overall survival by treatment arm (control vs research). C Event-free survival by treatment arm (including the dropped arm). D Overall survival by treatment arm (including the dropped arm). E Event-free survival by pathological complete response (excluding the dropped arm). F Overall survival by pathological complete response (excluding the dropped arm) in the mITT population. No adjustments were made for multiple comparisons. Source data is provided as a Source Data file.
Fig. 5 · Panel A
Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel B
Panel B 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel C
Panel C 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel D
Panel D 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel E
Panel E 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel F
Panel F 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。